| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:140-148.)
© 2008 American Heart Association, Inc.
Imaging |
From the Institut für Herz- und Kreislaufphysiologie (U.F., Z.D., C.J., J.S.) and Institut für Medizinische Mikrobiologie und Krankenhaushygiene (G.R.), Heinrich-Heine-Universität, Düsseldorf; Lehrstuhl für Pharmazeutische Technologie und Biopharmazie, Albert-Ludwigs-Universität Freiburg, Freiburg (H.H., R.S.); and Neurologische Klinik, Universitätsklinikum Düsseldorf, Düsseldorf (S.J.), Germany.
Correspondence to Ulrich Flögel, PhD, Institut für Herz- und Kreislaufphysiologie, Heinrich-Heine-Universität, Postfach 101007, 40001 Düsseldorf, Germany. E-mail floegel{at}uni-duesseldorf.de
Received September 4, 2007; accepted April 28, 2008.
Background— In this study, we developed and validated a new approach for in vivo visualization of inflammatory processes by magnetic resonance imaging using biochemically inert nanoemulsions of perfluorocarbons (PFCs).
Methods and Results— Local inflammation was provoked in 2 separate murine models of acute cardiac and cerebral ischemia, followed by intravenous injection of PFCs. Simultaneous acquisition of morphologically matching proton (1H) and fluorine (19F) images enabled an exact anatomic localization of PFCs after application. Repetitive 1H/19F magnetic resonance imaging at 9.4 T revealed a time-dependent infiltration of injected PFCs into the border zone of infarcted areas in both injury models, and histology demonstrated a colocalization of PFCs with cells of the monocyte/macrophage system. We regularly found the accumulation of PFCs in lymph nodes. Using rhodamine-labeled PFCs, we identified circulating monocytes/macrophages as the main cell fraction taking up injected nanoparticles.
Conclusions— PFCs can serve as a "positive" contrast agent for the detection of inflammation by magnetic resonance imaging, permitting a spatial resolution close to the anatomic 1H image and an excellent degree of specificity resulting from the lack of any 19F background. Because PFCs are nontoxic, this approach may have a broad application in the imaging and diagnosis of numerous inflammatory disease states.
Related Article:
This article has been cited by other articles:
![]() |
A. Saraste, S. G. Nekolla, and M. Schwaiger Cardiovascular molecular imaging: an overview Cardiovasc Res, September 1, 2009; 83(4): 643 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF] |
||||
![]() |
E. A. Osborn and F. A. Jaffer The year in molecular imaging. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 97 - 113. [Full Text] [PDF] |
||||
![]() |
A. J. Sinusas, F. Bengel, M. Nahrendorf, F. H. Epstein, J. C. Wu, F. S. Villanueva, Z. A. Fayad, and R. J. Gropler Multimodality Cardiovascular Molecular Imaging, Part I Circ Cardiovasc Imaging, November 1, 2008; 1(3): 244 - 256. [Full Text] [PDF] |
||||
![]() |
J. Schwitter Extending the Frontiers of Cardiac Magnetic Resonance Circulation, July 8, 2008; 118(2): 109 - 112. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |